ArticleResearch and practice in thrombosis and haemostasis2026
Country-level prediction of blood type distribution in hemophilia A in support of factor VIII consumption.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemophilia A is an inherited bleeding disorder resulting from a lack of factor (F)VIII. Patients with blood type O show faster decay in their FVIII pharmacokinetics and may require higher usage of factor concentrate. Although country-level blood type distribution among persons with hemophilia A is not well characterized, its alignment with the general population may offer a useful basis for prediction. Objectives: This study compared FVIII usage across blood types and assessed whether the distribution of blood types differs between general population and persons with hemophilia A. Methods: Data were extracted from the WAPPS-Hemo research database for the hemophilia A cohort and from an online source for the general population. Factor VIII pharmacokinetics and usage differences were assessed using analysis of variance. Poisson log-linear regression models described crosscountry counts of blood types. Congruence between blood type distributions of persons with hemophilia A and general populations was assessed by likelihood ratio test. Results: Factor VIII pharmacokinetics and usage was significantly different in patients with blood type O. Likelihood ratio test comparison showed no significant difference between both cohorts, with Poisson regression describing reasonably well the count and distribution across blood types. Conclusion: Patients with blood type O were found to require more FVIII on average. Predicting blood type distributions in persons with hemophilia A is enabled by their statistical similarity to the general population, potentially supporting country-level management of FVIII accessibility. Since South and Latin American countries showed a higher blood type O incidence, persons with hemophilia A from these populations may require a higher FVIII usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.